drugset / Trial / NCT05414500
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Phase 1
Suspended
10 enrolled
University of Alabama at Birmingham
Kyowa Kirin, Inc. · collabSeagen Inc. · collab
NaSequentialOpen-labelTreatment
Summary
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2027-06-30
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | — | Intravenous |
| Subject | Mogamulizumab | Monoclonal antibody | 1 mg/kg | Intravenous |